Clinical trials: Malignant Melanoma
Melanoma
Sitravatinib With or Without Tislelizumab in Patients With Unresectable or Metastatic Melanoma
In 2014, an estimated 7,000 patients were diagnosed of melanoma in China. It is growing at an annual rate of 3%-5% and approximately 20,000 new cases are reported each year recently.To date, CFDA only approved dacarbazine as…
- Trial name
- NCT05104801
- Testing
- sitravatinib, tislelizumab
- Where
- China
- Volunteers
- 37 people
- Sponsor
- Peking University Cancer Hospital & Institute
Melanoma (Skin)
Nitrocamptothecin in Treating Patients With Metastatic Melanoma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of nitrocamptothecin in treating patients who have…
- Trial name
- NCT00005875
- Testing
- rubitecan
- Where
- United States
- Sponsor
- Astex Pharmaceuticals, Inc.
Uveal Malignant Melanoma
Liver Transplantation and Uveal Malignant Melanoma
Patients with uveal malignant melanoma with liver metastases have median survival of less than 12 months. There is no established treatment showing increased overall survival.
- Trial name
- NCT01311466
- Testing
- Liver transplantation
- Where
- Norway
- Volunteers
- 2 people
- Sponsor
- Oslo University Hospital
Metastatic Melanoma
eFLASH for Skin Lesions of Malignant Melanomas
This prospective single center phase I trials aims to assess feasibility and safety of electron FLASH RT for treatment of melanoma skin metastases.
- Trial name
- Flash-Skin I (NCT06549439)
- Testing
- Electron FLASH radiotherapy
- Where
- Switzerland
- Volunteers
- 7 people
- Sponsor
- University of Zurich
Melanoma (Skin), Basal Cell Carcinoma
Use of Electrical Impedance Spectroscopy (EIS) for Early Diagnosis of Skin Damage
The purpose of this clinical study is to evaluate if the DermaSense prototype EIS scanner can provide medical decision support which can complement dermoscopy-based identification of the disease at time of biopsy decision.
- Conditions
- Melanoma (Skin), Basal Cell Carcinoma, Squamous Cell Carcinoma, Dysplastic Nevus Syndrome
- Trial name
- DermaSense (NCT04688749)
- Testing
- Electrical Impedence Spectroscopy DermaSense
- Where
- Greece
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Aristotle University Of Thessaloniki
Melanoma
Dietary Intervention in Patients with a History of Melanoma
This research trial studies the effects of diet in patients with a history of melanoma. We are studying the impact of 2 different diets; a whole-foods, fiber-rich diet and a ketogenic diet.
- Trial name
- NCT03950635
- Testing
- Dietary Intervention, Questionnaire Administration
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- M.D. Anderson Cancer Center
Melanoma, Lymphoma
A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)
Researchers are looking for new ways to treat children with different types of melanoma (skin cancer), solid tumors, and lymphomas (blood cancers) that are any of these: Advanced, which means cancer spread in the body or cannot…
- Conditions
- Melanoma, Lymphoma, Solid Tumor, Classical Hodgkin Lymphoma
- Trial name
- NCT02332668
- Testing
- Pembrolizumab
- Where
- 16 sites in United States, Brazil and 8 more
- Volunteers
- 370 people
- Sponsor
- Merck Sharp & Dohme LLC
Advanced Melanoma, Clinical Stage III Cutaneous Melanoma AJCC v8
Using Biomarkers to Help Guide Safe Immunotherapy Discontinuation in Patients With Unresectable Stage IIIB-IV Melanoma, The PET-Stop Trial
This phase II trial investigates how well biomarkers on PET/CT imaging drive early discontinuation of anti-PD-1 therapy in patients with stage IIIB-IV melanoma that cannot be removed by surgery (unresectable).
- Conditions
- Advanced Melanoma, Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Melanoma of Unknown Primary
- Trial name
- NCT04462406
- Testing
- Ipilimumab, Nivolumab, Patient Observation
- Where
- 482 sites in United States
- Volunteers
- 150 people
- Sponsor
- ECOG-ACRIN Cancer Research Group
Melanoma
MAGE-A3 Antigen-Specific Cancer Immunotherapeutic in Patients With Progressive Metastatic Cutaneous Melanoma
This study is being done to evaluate the safety and the clinical activity of MAGE-A3 Antigen-Specific Cancer Immunotherapeutic in patients with unresectable and progressive metastatic cutaneous melanoma.
- Trial name
- NCT00706238
- Testing
- GSK Biologicals' Recombinant MAGE-A3 Antigen-Specific Cancer Immunotherapeutic (ASCI) GSK1203486A
- Where
- 6 sites in Argentina, Greece and 1 more
- Volunteers
- 5 people
- Sponsor
- GlaxoSmithKline
Malignant Neoplasms
A Study of DEG6498 in Participants With Solid Tumors
The goal of this first in human, Phase 1, multi-center, open-label, and 2-part study is to learn whether DEG6498 is safe and tolerable in participants with advanced solid tumors.
- Trial name
- NCT07244835
- Testing
- DEG6498
- Where
- 3 sites in China
- Volunteers
- 100 people
- Sponsor
- Degron Therapeutics Co.
Neoplasms, Melanoma
A Study of Modakafusp Alfa (TAK-573) Given by Itself and Together With Pembrolizumab in Adults With Advanced or Metastatic Solid Tumors
This study has 2 phases. The main aims of Phase 1b are: to check for side effects from modakafusp alfa in adults with locally advanced or metastatic solid tumors.
- Trial name
- NCT04157517
- Testing
- Modakafusp Alfa, Pembrolizumab
- Where
- 17 sites in United States, Australia
- Volunteers
- 45 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D LLC
Lung Cancer, Oral Cancer
Exploratory Study of Inhaled Afatinib Dimaleate PK Profile
This is a pilot Phase I open-label randomized single-dose two-period crossover study (in the EDDIS project) evaluating the bioequivalence, pharmacokinetics (PK), safety, and tolerability of inhaled afatinib dimaleate compared…
- Conditions
- Lung Cancer, Oral Cancer, Melanoma
- Trial name
- EDDIS-a1 (NCT06897735)
- Testing
- Afatinib Dimaleat, inhalation of afatinib dimaleate
- Where
- New Zealand
- Volunteers
- 4 people, healthy volunteers welcome
- Sponsor
- Petrov, Andrey
Gastric Adenocarcinoma, Malignant Melanoma
This Study is a Phase II Study of AZD6738 in Combination With Durvalumab in Patients With Solid Tumor (Cohort A (N=30): GC Who Have Failed Secondary Chemotherapy Treatments Regimen; Cohort B (B=30): Melanoma Patients Who Have Failed to IO)
This study is a phase II study of AZD6738 in combination with durvalumab in patients with solid tumor (cohort A (N=30): GC who have failed secondary chemotherapy treatments regimen; cohort B (B=30): melanoma patients who have…
- Trial name
- NCT03780608
- Testing
- AZD6738, Durvalumab
- Where
- South Korea
- Volunteers
- 61 people
- Sponsor
- Samsung Medical Center
Metastatic Melanoma, Renal Cell Cancer
Mechanism of Action of High-Dose IL-2 (Aldesleukin) in Metastatic Melanoma and Kidney Cancer
Background: -Although IL-2 can shrink tumors in about 20 percent of patients with metastatic kidney cancer and in 15 percent of patients with metastatic melanoma, it is not fully known how the drug works.
- Trial name
- NCT00304460
- Testing
- aldesleukin
- Where
- United States
- Volunteers
- 138 people
- Sponsor
- National Cancer Institute (NCI)
Neuroblastoma, Melanoma
A Phase I Trial Of The Humanized Anti-GD2 Antibody In Children And Adolescents With Neuroblastoma, Osteosarcoma, Ewing Sarcoma and Melanoma
Relapsed and/or refractory neuroblastoma, osteosarcoma, Ewing sarcoma and melanoma are considered difficult to treat and cure. For this study we are testing the use of a new experimental (investigational) antibody called…
- Conditions
- Neuroblastoma, Melanoma, Osteosarcoma, Ewing Sarcoma
- Trial name
- NCT00743496
- Testing
- Anti-GD2 antibody
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- St. Jude Children's Research Hospital
Kidney Cancer, Melanoma (Skin)
Genistein and Interleukin-2 in Treating Patients With Metastatic Melanoma or Kidney Cancer
RATIONALE: Genistein may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Trial name
- NCT00276835
- Testing
- High-dose interleukin-2, genistein
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Northwestern University
Melanoma, Non-small Cell Lung Cancer
A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies
This is a study to determine the maximum tolerated dose (MTD) for CDX-1140 (CD40 antibody), either alone or in combination with CDX-301 (FLT3L), pembrolizumab, or chemotherapy and to further evaluate its tolerability and efficacy…
- Conditions
- Melanoma, Non-small Cell Lung Cancer, Breast Cancer, Gastric Cancer
- Trial name
- NCT03329950
- Testing
- CDX-1140, CDX-301, pembrolizumab
- Where
- 11 sites in United States
- Volunteers
- 132 people
- Sponsor
- Celldex Therapeutics
Mucosal Lentiginous Melanoma, Acral Lentiginous Malignant Melanoma
SU011248 in Patients With Metastatic Mucosal or Acral/Lentiginous Melanoma
The purpose of this study is to evaluate how effective Sunitinib works in treating acral lentiginous and mucosal melanoma which has spread beyond the local region.
- Trial name
- NCT00577382
- Testing
- Sunitinib
- Where
- 5 sites in United States
- Volunteers
- 52 people
- Sponsor
- Dana-Farber Cancer Institute
Metastatic Melanoma
A Personal Cancer Vaccine (NEO-PV-01) and APX005M or Ipilimumab With Nivolumab in Patients With Advanced Melanoma
The primary purpose of this study is to demonstrate that the NEO-PV-01 vaccine, either with APX005M or ipilimumab, and nivolumab is safe for the treatment of patients with advanced or metastatic melanoma.
- Trial name
- NCT03597282
- Testing
- NEO-PV-01, Nivolumab, Adjuvant
- Where
- 8 sites in United States
- Volunteers
- 22 people
- Sponsor
- BioNTech US Inc.
Melanoma
Anti-PD-1 Antibody With HD IL-2 in Metastatic Melanoma
The primary objective of this single arm phase 2 trial is to assess the response rate [complete response (CR) + partial response (PR)] of sequential therapy of pembrolizumab followed by HD IL-2 in subjects with stage IV malignant…
- Trial name
- NCT03476174
- Testing
- Pembrolizumab, Interleukin-2
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Ralph Hauke
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.